Real-life Study on the Use of Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Relapsed/Refractory Multiple Myeloma

A multicenter, non-interventional, observational, retrospective and prospective pharmacological study aimed at evaluating the use of allogeneic hematopoietic stem cell transplantation in patients with relapsed/refractory multiple myeloma.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Plasma Cell Neoplasms Blood Protein Disorders Cardiovascular Diseases Hematologic Diseases Hemic and Lymphatic Diseases Hemorrhagic Disorders Hemostatic Disorders Immune System Diseases Immunoproliferative Disorders Lymphoproliferative Disorders Multiple Myeloma Neoplasms Neoplasms by Histologic Type Neoplasms, Plasma Cell Paraproteinemias Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Dipartimento di Medicina e Scienze dell'Invecchiamento, Università degli Studi "G. d'Annunzio" di Chieti - Pescara

Chieti, CH, 66100, Italy

Location status: Recruiting

Location contact

Carmine Liberatore, MD

CONTACT

[email protected]

+390854251

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

patients diagnosed with relapsed/refractory multiple myeloma according to IMWG criteria who have undergone allogeneic hematopoietic stem cell transplantation;
Age ≥ 18 years;
Signature of the informed consent form (where possible).

Exclusion criteria

Patients diagnosed with primary AL amyloidosis, monoclonal gammopathy of undetermined significance (MGUS), indolent multiple myeloma, or primary plasma cell leukemia;
Patients who have not undergone allogeneic hematopoietic stem cell transplantation;
Age < 18 years.

Treatment and study plan

Primary outcomes

Progression-free survival (PFS)

Time frame: 10 years from the date of allogeneic hematopoietic stem cell transplantation.

Progression-free survival (PFS) of patients with relapsed/refractory multiple myeloma undergoing allogeneic hematopoietic stem cell transplantation.

PFS is defined as time from the date of allogeneic hematopoietic stem cell transplantation to the date of confirmed disease progression, or the date of death from any cause, whichever comes first.

Study contacts

Contact information is provided by the study sponsor or research team.

Carmine Liberatore, MD

CONTACT

[email protected]

+390854252853

Sponsors and collaborators

Lead sponsor

Università degli Studi 'G. d'Annunzio' Chieti e Pescara

Other

Registry information

Official study title

Studio Real-life Sull'Utilizzo Del Trapianto Allogenico di Cellule Staminali Ematopoietiche in Pazienti Affetti da Mieloma Multiplo Recidivato Refrattario

Acronym: MAIELLA

Important dates

Study start: 2026
Primary completion: 2027
Study completion: 2027
First posted: Aug 20, 2026
Registry last updated: Aug 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not yet recruiting